319 related articles for article (PubMed ID: 33602681)
21. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.
Ross DS; Devereaux KA; Jin C; Lin DY; Zhang Y; Marra A; Makker V; Weigelt B; Ellenson LH; Chui MH
Mod Pathol; 2022 Jul; 35(7):962-971. PubMed ID: 34972830
[TBL] [Abstract][Full Text] [Related]
22. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
23. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
[TBL] [Abstract][Full Text] [Related]
25. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
[TBL] [Abstract][Full Text] [Related]
26. Pathology of Endometrial Carcinoma.
Lax SF
Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
[TBL] [Abstract][Full Text] [Related]
27. The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
Beinse G; Just PA; Rance B; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Pasmant E; Batteux F; Borghese B; Alexandre J; Leroy K
PLoS One; 2019; 14(3):e0214416. PubMed ID: 30908539
[TBL] [Abstract][Full Text] [Related]
28. Targeted mutation analysis of endometrial clear cell carcinoma.
Hoang LN; McConechy MK; Meng B; McIntyre JB; Ewanowich C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2015 Apr; 66(5):664-74. PubMed ID: 25308272
[TBL] [Abstract][Full Text] [Related]
29. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
[TBL] [Abstract][Full Text] [Related]
30. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
[TBL] [Abstract][Full Text] [Related]
31. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups.
Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
[TBL] [Abstract][Full Text] [Related]
32. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
Köbel M; Kang EY
Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of endometrial cancer and therapeutic implications.
Uppendahl L; Mullany SA; Winterhoff B
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):35-39. PubMed ID: 27941362
[TBL] [Abstract][Full Text] [Related]
34. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.
Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
[TBL] [Abstract][Full Text] [Related]
35. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
36. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
[TBL] [Abstract][Full Text] [Related]
37. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
[TBL] [Abstract][Full Text] [Related]
38. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
39. Activation of oxidative phosphorylation in TP53-inactive endometrial carcinomas with a poor prognosis.
Takahashi N; Hatakeyama K; Nagashima T; Ohshima K; Urakami K; Yamaguchi K; Hirashima Y
Int J Gynecol Cancer; 2021 Dec; 31(12):1557-1563. PubMed ID: 34725206
[TBL] [Abstract][Full Text] [Related]
40. [Endometrial carcinomas in 2021: What to say and what to do?].
Just PA; Genestie C
Ann Pathol; 2022 Mar; 42(2):104-112. PubMed ID: 34340872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
